BOSTON, Nov. 11,
2014 /PRNewswire/ -- PAREXEL International Corporation
(NASDAQ: PRXL), a leading global biopharmaceutical services
provider, today announced the opening of its new European
Coordination Hub and Distribution Center in Berlin-Schonefeld,
Germany. The facility expands the Company's capacity to
provide comprehensive clinical trial supply and logistics services
to support clients' local, regional and global trial
requirements. These capabilities include synchronized
coordination of clinical trial supplies, ancillary supplies and
central laboratory services.
"To safely and efficiently conduct clinical trials, our
customers need highly specialized clinical supply and logistics
services for studies that can span dozens of countries and hundreds
of sites around the world," said Mark A.
Goldberg, President and Chief Operating Officer, PAREXEL.
"Our new European distribution center reflects a commitment to
simplify the important end-to-end supply-management aspect of the
drug-development journey."
The facility features more than 65,000 cubic meters of storage
space. It offers lab-kit assembly and provides storage and
distribution of ancillary materials.
"Through this center, we can customize sourcing and distribution
strategies for customers in ways that are efficient, robust and
compliant with local regulations," said Thomas Senderovitz, Senior Vice President,
Clinical Research Services, PAREXEL. "In addition, from this
central location, we can provide responsive, timely delivery
services to all EU destinations."
The new European Coordination Hub and Distribution Center will
be licensed to store Investigational Medicinal Products (IMPs) and
Non-Investigational Medicinal Products (N-IMPs). It will also
offer secondary packaging, re-labeling, and compliance with Good
Distribution Practice (GDP) of medical devices and ambient,
refrigerated and frozen medicinal products, including controlled
substances. On-site Qualified Person (QP), Quality Control
(QC) and production personnel will manage regulatory-compliance
requirements. They will also streamline product import,
receipt, storage, packaging and labeling, release, shipment, return
and destruction timelines.
PAREXEL also is opening new full-service clinical trial supply
depots in Buenos Aires, Argentina,
and Sao Paulo, Brazil. The
facilities are part of PAREXEL's growing global system of more than
50 owned or in-network depots and three regional distribution
centers. They are designed to help ensure a seamless flow of
materials and timely clinical site supply delivery around the
world.
About PAREXEL International
PAREXEL International
Corporation is a leading global biopharmaceutical services
organization, providing a broad range of knowledge-based contract
research, consulting, medical communications, and technology
solutions and services to the worldwide pharmaceutical,
biotechnology and medical device industries. Committed to providing
solutions that expedite time-to-market and peak-market penetration,
PAREXEL has developed significant expertise across the development
and commercialization continuum, from drug development and
regulatory consulting to clinical pharmacology, clinical trials
management, medical education and reimbursement. PAREXEL
Informatics, Inc. provides advanced technology solutions, including
medical imaging, to facilitate the clinical development process.
Headquartered near Boston,
Massachusetts, PAREXEL operates in 81 locations in 51
countries around the world, and has approximately 15,980 employees.
For more information about PAREXEL International visit
www.PAREXEL.com.
PAREXEL is a registered trademark of PAREXEL International
Corporation or its affiliates.
This release contains "forward-looking" statements regarding
future results and events. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed forward-looking statements. Without limiting the foregoing,
the words "believes," "anticipates," "plans," "expects," "intends,"
"appears," "estimates," "projects," "will," "would," "could,"
"should," "targets," and similar expressions are also intended to
identify forward-looking statements. The forward-looking statements
in this release involve a number of risks and uncertainties. The
Company's actual future results may differ significantly from the
results discussed in the forward-looking statements contained in
this release. Important factors that might cause such a difference
include, but are not limited to, risks associated with: actual
operating performance; actual expense savings and other operating
improvements resulting from recent and anticipated restructurings;
the loss, modification, or delay of contracts which would, among
other things, adversely impact the Company's recognition of revenue
included in backlog; the Company's dependence on certain industries
and clients; the Company's ability to win new business, manage
growth and costs, and attract and retain employees; the Company's
ability to complete additional acquisitions, and to integrate newly
acquired businesses including the recent acquisitions of LIQUENT,
Inc. and HERON, Inc., or enter into new lines of business; the
impact on the Company's business of government regulation of the
drug, medical device and biotechnology industry; consolidation
within the pharmaceutical industry and competition within the
biopharmaceutical services industry; the potential for significant
liability to clients and third parties; the potential adverse
impact of health care reform; and the effects of exchange rate
fluctuations and other international economic, political, and other
risks. Such factors and others are discussed more fully in
the section entitled "Risk Factors" of the Company's Annual Report
on Form 10-K for the fiscal year ended June
30, 2014 as filed with the SEC on August 20, 2014, which "Risk Factors" discussion
is incorporated by reference in this press release. The Company
specifically disclaims any obligation to update these
forward-looking statements in the future. These forward-looking
statements should not be relied upon as representing the Company's
estimates or views as of any date subsequent to the date of this
press release.
Contacts:
Diana Martin,
Vice President, Corporate Communications
PAREXEL International
Tel: +1 781-434-5516
Email: Diana.Martin@PAREXEL.com
Matthew Briggs
PAN Communications
Tel: +1 617-502-4300
Email: PAREXEL@pancomm.com
Photo - http://photos.prnewswire.com/prnh/20141107/157408
SOURCE PAREXEL International Corporation